<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04091828</url>
  </required_header>
  <id_info>
    <org_study_id>cognition in bipolar patients</org_study_id>
    <nct_id>NCT04091828</nct_id>
  </id_info>
  <brief_title>Assessment of Cognitive Functions in Bipolar Patients</brief_title>
  <official_title>Assessment of Cognitive Functions in Bipolar Disorder Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment of cognitive function in manic bipolar patient
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Assessment of severity of mania and depression in bipolar patients then evaluate their
      cognitive function.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2019</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>4 Years</target_duration>
  <primary_outcome>
    <measure>Assessment of severity of mania in bbipolar patients</measure>
    <time_frame>2019-2022</time_frame>
    <description>EVALUATE manic patients by Young Mania Rating Scale (YMRS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of severity of depression in bipoiar patients</measure>
    <time_frame>2019-2022</time_frame>
    <description>Evaluate depressed patients by Hamilton Rating Scale for depression(HRS).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of cognitive function in bipoiar patients</measure>
    <time_frame>2019-2022</time_frame>
    <description>Evaluate cognition in included patients by Montreal Cognitive Assessment(MOCA) and P300.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between cognitive state in bipolar patient and(onset age,illness duration and number of episodes).</measure>
    <time_frame>2019-2021</time_frame>
    <description>from history</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>Biplar patients</arm_group_label>
    <description>diagnosed by DSM-5 and divided to manic,depressed and mixed last episod</description>
  </arm_group>
  <arm_group>
    <arm_group_label>controlled subject</arm_group_label>
    <description>not have any medical or psychatric problem affect cognition</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        stable people not irritable
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 18-55 years

          -  Of both sex

          -  Diagnosed as bipolar by DSM-5(patient)

        Exclusion Criteria:

          -  Current medical and psychiatric comorbidities which may affect cognitive status.

          -  Substance abuse or dependence (except nicotine and caffeine)in last month.

          -  Somatic treatment with drugs known to affect cognitive status (cortisol,
             antihistamines, etc.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 5, 2019</study_first_submitted>
  <study_first_submitted_qc>September 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2019</study_first_posted>
  <last_update_submitted>September 25, 2019</last_update_submitted>
  <last_update_submitted_qc>September 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Marwa Salama Ahmed Omar</investigator_full_name>
    <investigator_title>Assessment of cognitive function in bipolar patients</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

